In this downloadable slideset, Paul Y. Kwo, MD, reviews current and forthcoming options for interferon-free treatment of pretransplantation and posttransplantation patients with HCV.
In this downloadable slideset, Jean C. Edmond, MD, offers insight into managing HCV in pretransplant and posttransplant patients.
In this downloadable slideset, Norah Terrault, MD, MPH, leads a review of a series of cases with Jean C. Emond, MD, and Paul Y. Kwo, MD, evaluating the optimal use of available HCV therapies in the pretransplantation and posttransplantation patients.
Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
Now that highly tolerable, highly effective HCV treatments are available, treatment in the pretransplant setting is a viable approach for many patients currently on the waitlist. Does this approach have a downside?
In starting HCV treatment after liver transplant, how soon is soon enough?
Will we finally have options to prevent posttransplantation HCV recurrence across the spectrum of genotypes?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.